| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000212 | Meiotic spindle organization | Decreases phenotype | PMID:34509492 |
| GO:0004784 | Superoxide dismutase activity | Increases phenotype | PMID:34699866 |
| GO:0006309 | Apoptotic dna fragmentation | Increases phenotype | PMID:18840529 |
| GO:0006914 | Autophagy | Increases phenotype | PMID:20587533 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:18840529; PMID:21750559; PMID:34509492 |
| GO:0007005 | Mitochondrion organization | Decreases phenotype | PMID:34509492 |
| GO:0008283 | Cell population proliferation | Affects phenotype | PMID:18840529; PMID:3097147 |
| GO:0016049 | Cell growth | Decreases phenotype | PMID:39263880 |
| GO:0016477 | Cell migration | Increases phenotype | PMID:39263880 |
| GO:0031941 | Filamentous actin | Increases phenotype | PMID:39263880 |
| GO:0040038 | Polar body extrusion after meiotic divisions | Decreases phenotype | PMID:34509492 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:35872041 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:39263880 |
| GO:0044319 | Wound healing, spreading of cells | Decreases phenotype | PMID:39263880 |
| GO:0046034 | Atp metabolic process | Affects phenotype | PMID:34509492 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:21750559; PMID:34509492 |
| GO:0060326 | Cell chemotaxis | Affects phenotype | PMID:39263880 |
| GO:0070192 | Chromosome organization involved in meiotic cell cycle | Decreases phenotype | PMID:34509492 |
| GO:0070265 | Necrotic cell death | Increases phenotype | PMID:34699866 |
| GO:0070994 | Detection of oxidative stress | Affects phenotype | PMID:34699866 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:34509492 |
| GO:1903047 | Mitotic cell cycle process | Decreases phenotype | PMID:34699866 |
| GO:1903537 | Meiotic cell cycle process involved in oocyte maturation | Affects phenotype | PMID:34509492 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.